6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage.

6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage. Oncol Lett. 2019 Dec;18(6):6917-6925 Authors: Nekrasov KA, Vikarchuk MV, Rudenko EE, Ivanitskiy IV, Grygorenko VM, Danylets RO, Kondratov AG, Stoliar LA, Sharopov BR, Kashuba VI Abstract The detection of prostate cancer (PCa) biomarkers in bodily fluids, a process known as liquid biopsy, is a promising approach and particularly beneficial when performed in urine samples due to their maximal non-invasiveness requirement of collection. A number of gene panels proposed for this purpose have allowed discrimination between disease-free prostate and PCa; however, they bear no significant prognostic value. With the purpose to develop a gene panel for PCa diagnosis and prognosis, the methylation status of 17 cancer-associated genes were analyzed in urine cell-free DNA obtained from 31 patients with PCa and 33 control individuals using methylation-specific polymerase chain reaction (MSP). Among these, 13 genes indicated the increase in methylation frequency in patients with PCa compared with controls. No prior association has been reported between adenomatosis polyposis coli 2 (APC2), homeobox A9, Wnt family member 7A (WNT7A) and N-Myc downstream-regulated gene 4 protein genes with PCa. The 6-gene panel consisting of APC2, cadherin 1, forkhead box P1, leucine rich repeat containing 3B, WNT7A a...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research